Neurotropic therapy in patients with hearing impairment with chronic cerebral ischemia: an open, uncontrolled study

Aim. To identify sensorineural hearing loss and ear noise in patients with chronic cerebral ischemia on an outpatient basis, and to evaluate the experience of using combined neurotropic therapy in this category of patients.
Material and methods. The study included 50 patients with chronic cerebral ischemia (CIG), with hearing impairments of varying degrees, ear noise, vestibular, cerebro-asthenic syndrome, and who had an outpatient appointment with a neurologist. All patients underwent a scale assessment of VAS – a visually analog scale of ear noise, VAS-G – a visually analog scale of dizziness, THI – a subjective scale for assessing the severity of ear noise, MFI-20 – a scale of severity of asthenia. All patients in the study group were treated with сellex on the background of complex therapy in the form of two courses of therapy with an interval of 20 days. Before the start of treatment, after the end of the first and second courses of treatment, testing was carried out according to appropriate scales and questionnaires, as well as otoneurological and audiological examinations.
Results. In the study group of patients, a varying degree of sensorineural hearing loss was detected, as well as a high comorbid background, with most patients experiencing subjective noise of varying intensity, as well as moderately pronounced vestibular syndrome and cerebral asthenic syndrome. After the complex treatment, there was a statistically significant subjective improvement in hearing and speech intelligibility, as well as a statistically significant decrease in indicators on the scales of subjective assessment of noise and dizziness, a decrease in general, physical and mental asthenia. The most statistically significant difference in positive changes was noted after a second course of therapy.
In conclusion, the positive results of this study can be considered a decrease in the severity and severity of symptoms of sensorineural hearing loss, which achieved statistically significant improvement after the second course of therapy, a decrease in the manifestations of ear noise, a decrease in asthenia, a decrease in the feeling of dizziness and instability against the background of neurotropic therapy with сellex. In this situation, preference should be given to drugs with a multimodal mechanism of action, potentially affecting various levels of disorders in vascular pathology of the brain, including the auditory analyzer, as well as contributing to the processes of neuroplasticity of the brain.